Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1992-04-01
1993-01-05
Cashion, Jr., Merrell C.
Drug, bio-affecting and body treating compositions
Lymphokine
514 77, A61K 3940, A61K 3704, A61K 31665, A61K 31425
Patent
active
051769085
ABSTRACT:
The invention is a method of treating endotoxic shock in a mammal which comprises administering to the mammal a therapeutically effective amount of an antagonist to Platelet Activating Factor in combination with a therapeutically effective amount of one or more monoclonal or polyclonal antibodies directed towards either Tumor Necrosis Factor .alpha., Interleukin-1.beta., Gamma Interferon, or bacterial cell wall lipopolysaccharides.
REFERENCES:
patent: 4148879 (1979-04-01), Nelson
F. H. Valone et al.: "Biphasic Platelet-Activating Factor Synthesis by Human Monocytes Stimulated with IL-1-beta, Tumor Necrosis Factor, or IFN-gamma.sup.1 ", The Journal of Immunology, vol. 141, No. 11, Dec. 1, 1988, pp. 3945-3950, The American Association of Immunologists.
Tracey et al.: Science, vol. 234, Oct. 24 (1986), pp. 470-474.
Beutler et al.: Science, vol. 229, Aug. 30 (1985), pp. 869-871.
Terashita et al.: European Journal of Pharmacology, vol. 109, (1985), pp. 257-261.
Kerwar Suresh S.
Kohler Constance
Wissner Allan
American Cyanamid Company
Cashion Jr. Merrell C.
Jackson H. G.
Koh Choon P.
LandOfFree
Method for the treatment of endotoxic shock in mammal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of endotoxic shock in mammal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of endotoxic shock in mammal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2389858